Heart Health Co. Sues Rival Over Genetic Test Patent

Law360, Washington (December 09, 2013, 8:04 PM ET) -- Heart health management company Boston Heart Diagnostics Corp. launched a suit in Massachusetts federal court Monday alleging a laboratory testing company's genetic testing for statin-induced myopathy risk violates Boston Heart's licensed patent for the same testing.

Boston Heart informed Health Diagnostic Laboratory Inc. that its genetic testing infringed U.S. Patent No. 8,455,194, which covers diagnostic methods for identifying individuals who are at risk of severe muscle aches and pains, or myopathy, caused by statin drugs used to reduce cholesterol levels.

But Boston Heart claims HDL has...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers


Case Information

Case Title

Boston Heart Diagnostics Corporation v. HEALTH DIAGNOSTIC LABORATORY, INC.

Case Number




Nature of Suit



F. Dennis Saylor, IV

Date Filed

December 8, 2013


Law Firms Mentioned